Donald O. Schnuck Family Professor, Neurology, Washington University School of Medicine; Director, Washington University Neurofibromatosis Center
Neurology
Dr. David H. Gutmann, MD
|
|
Give Review
David Gutmann practices Neurology. He went to University of Michigan Medical School. He has 4 awards "Riley-Church Lectureship", "Distinguished Faculty Research Award", "Frederich Von Recklinghausen Award" and "Elected Member". David Gutmann is also a published doctor. He has 103 publication published. The most recent publication is: Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1.
Publications
- De novo development of gliomas in a child with neurofibromatosis type 1, fragile X and previously normal brain magnetic resonance imaging.
- Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral Nerve sheat...
- 3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.
- NF1 Germline Mutation Differentially Dictates Optic Glioma Formation and Growth in Neurofibromatosis-1.
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
- HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.
- RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth.
- Improving outcomes for neurofibromatosis 1-associated brain Tumors.
- Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.
- Activated K-Ras, but not H-Ras or N-Ras, regulates brain neural stem cell proliferation in a Raf/Rb-dependent manner.
- Elucidating the Impact of Neurofibromatosis-1 Germline Mutations on Neurofibromin Function and Dopamine-Based Learning.
- The mTOR signaling pathway as a treatment target for intracranial neoplasms.
- A multidisciplinary approach in neurofibromatosis 1-Authors' reply.
- NF GEMMs already! The power and promise of mouse tumor models.
- Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.
- Parental age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative.
- Validity of participant-reported diagnoses in an online patient registry: A report from the NF1 Patient Registry Initiative.
- Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
- The cyclic AMP pathway is a sex-specific modifier of glioma risk in type 1 neurofibromatosis patients.
- Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenues.
- Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study.
- Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions.
- Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma.
- Update from the 2013 international neurofibromatosis conference.
- RNA-sequencing reveals oligodendrocyte and neuronal transcripts in microglia relevant to central nervous system disease.
- Morphologic and immunohistochemical features of malignant peripheral Nerve sheath tumors and cellular schwannomas.
- The impact of coexisting genetic mutations on murine optic glioma biology.
- Neurofibromatosis type 1: a multidisciplinary approach to care.
- Eliminating barriers to personalized medicine: Learning from neurofibromatosis type 1.
- Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis.
- Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
- A Pilot Study for Evaluation of Hypotonia in Children With Neurofibromatosis Type 1.
- cDNA Hybrid Capture Improves Transcriptome Analysis on Low-Input and Archived Samples.
- Evaluation of participant recruitment methods to a rare disease online registry.
- Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma.
- Glomus Tumors in individuals with neurofibromatosis type 1.
- Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity.
- CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
- BRAF-V600E mutation in pediatric and adult glioblastoma.
- Sex is a major determinant of neuronal dysfunction in Neurofibromatosis Type 1.
- BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral Nerve sheath tumors.
- Longitudinal analysis of developmental delays in children with neurofibromatosis type 1.
- The association between hypotonia and brain Tumors in children with neurofibromatosis type 1.
- Functional outcome measures for NF1-associated optic pathway glioma clinical trials.
- Erratum to: Optic Nerve tortuosity in children with neurofibromatosis type 1.
- Epilepsy in individuals with neurofibromatosis type 1.
- Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1.
- A neuropsychological perspective on attention problems in neurofibromatosis type 1.
- Advances in the treatment of neurofibromatosis-associated tumours.
- Conditional KIAA1549:BRAF mice reveal brain region- and cell type-specific effects.
- Antiangiogenic agents for nonmalignant brain Tumors.
- Optic Nerve tortuosity in children with neurofibromatosis type 1.
- Teaching NeuroImages: T2 hyperintensities in neurofibromatosis type 1.
- The molecular and cell biology of pediatric low-grade gliomas.
- BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma.
- Assessment of Pain and Itch Behavior in a Mouse Model of Neurofibromatosis Type 1.
- Development of an international internet-based neurofibromatosis Type 1 Patient registry.
- Height assessments in children with neurofibromatosis type 1.
- Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.
- Optimizing biologically targeted clinical trials for neurofibromatosis.
- NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma.
- Modeling cognitive dysfunction in neurofibromatosis-1.
- Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma.
- MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2.
- Attention skills in children with neurofibromatosis type 1.
- Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.
- Deconvoluting mTOR biology.
- Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.
- Developmental Delays in Children With Neurofibromatosis Type 1.
- Low-grade gliomas as neurodevelopmental disorders: Insights from mouse models of neurofibromatosis-1.
- PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.
- Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.
- Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis.
- Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner.
- Identification of transcriptional regulatory networks specific to pilocytic astrocytoma.
- Report from the fifth national cancer institute mouse models of human cancers consortium nervous system Tumors workshop.
- Comparative Characterization of the Human and Mouse Third Ventricle Germinal Zones.
- Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral Nerve sheath tumor.
- Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.
- Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.
- Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays.
- Rethinking pediatric gliomas as developmental brain abnormalities.
- Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.
- Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes.
- Postoperative imaging surveillance in pediatric pilocytic astrocytomas.
- Fatty acid synthase as a novel target for meningioma therapy.
- Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.
- Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity.
- The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
- Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop.
- Preclinical in vivo evaluation of rapamycin in human malignant peripheral Nerve sheath explant xenograft.
- Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.
- Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and Back.
- Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature.
- Brainstem glioma presenting as pruritus in children with neurofibromatosis-1.
- Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.
- Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1.
- Histopathologic predictors of pilocytic astrocytoma event-free survival.
- Optic Nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma.
- The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner.
- Associations between allergic conditions and pediatric brain Tumors in Neurofibromatosis type 1.
- Peri-gestational risk factors for pediatric brain Tumors in Neurofibromatosis Type 1.
Schools
University Of Michigan Medical School
Hospital University Penn
University Mich
Conditions Treated
- Ataxia
- Low Back Background: yellow;'>Pain
- Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Nerve Sheath Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Background: yellow;'>Tumors
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- Riley-Church Lectureship
- Distinguished Faculty Research Award
- Frederich Von Recklinghausen Award
- Elected Member
Education
-
University of Pennsylvania Health System -
University of Michigan Medical School
Hospital
-
St. Louis Children's Hospital -
Barnes-Jewish Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Thomas J. Geller, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos M. Yu II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Walter Lemann III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick A. Hogan, MD |
|
|
Dr. Edward F. Vastola, MD |
|
|
Dr. James E. Alonso, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maurizio Corbetta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mwiza Ushe, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John B. Selhorst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francis A. Mithen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David F. Mendelson, MD |
|
|
Dr. Kevin Patel, MD |
|
|
Dr. Jason A. Helis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Seth L. Hepner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Momina Soudagar Turkey, MD |